Sublocade Maker Indivior to Merge With Supernus in All-Stock Deal

Indivior Pharmaceuticals, the maker of Sublocade, the once-monthly buprenorphine injection that has become the dominant long-acting treatment for opioid use disorder in the United States, announced Monday that it will merge with Supernus Pharmaceuticals in a tax-free, all-stock merger of equals creating a central nervous system company with roughly $2.2 billion in combined annual revenue.

The transaction, unanimously approved by both boards and expected to close in the fourth quarter of 2026, folds the single most important commercial product in medication-based addiction treatment into an 11-drug portfolio spanning psychiatry, neurology, and addiction medicine.

The terms of the deal

Under the agreement, Supernus stockholders will receive 1.5401 Indivior shares for each Supernus share, while Indivior stockholders collect a one-time special cash dividend of $1 billion immediately before closing, financed in part through a $650 million term loan from Citibank. When the dust settles, former Indivior shareholders will own about 56.5 percent of the combined company, with Supernus shareholders holding 43.5 percent on a fully diluted basis.

The merged entity keeps the Supernus name and the Nasdaq ticker SUPN, with global headquarters in Rockville, Maryland. Supernus chief executive Jack Khattar will lead the combined company, and Indivior board member Tony Kingsley will serve as board chair of an eight-member board split evenly between the two organizations. The companies project $125 million in annual cost synergies, approximately $888 million in adjusted operating earnings, and net debt of about $878 million.

Asked about job impacts on Monday's investor call, Khattar said "natural redundancies" tied to the savings target could be expected, particularly in general and administrative roles. No specific workforce figures were disclosed.

Sublocade anchors the addiction business

The strategic centerpiece of the deal is Sublocade, which generated $253 million in second-quarter revenue and accounts for roughly 76 percent of the U.S. market for opioid use disorder medication, according to a Jefferies analyst note cited by BioSpace. Indivior's leadership has expressed confidence in the drug's exclusivity runway, with patent protection stretching through at least 2038.

Sublocade's appeal is clinical as much as commercial. The monthly injection eliminates the daily dosing burden of transmucosal buprenorphine, reduces diversion risk, and keeps patients covered against overdose for weeks at a time — properties that have made long-acting formulations a priority in medication-assisted treatment programs from community clinics to correctional facilities. More than 500,000 patients have been prescribed the formulation, according to data Indivior presented at the American Society of Addiction Medicine's annual conference earlier this year.

Supernus brings a different kind of CNS portfolio: Qelbree, a non-stimulant ADHD medication that posted $89 million in second-quarter sales; Gocovri for Parkinson's disease; and Zurzuvae, the postpartum depression treatment acquired in Supernus's $795 million buyout of Sage Therapeutics last year.

A company reshaped since its Suboxone reckoning

For Indivior, the merger caps a years-long effort to move past one of the ugliest chapters in the opioid industry's legal history. In 2020, the company's Indivior Solutions unit pleaded guilty to a felony charge and Indivior entities agreed to pay $600 million to resolve criminal and civil liability over the marketing of Suboxone, the sublingual buprenorphine film that built the company.

The Richmond, Virginia-based company subsequently restructured around what it called the Indivior Action Agenda, pivoting its commercial focus toward Sublocade and away from its legacy products. Indivior chief executive Joe Ciaffoni framed Monday's announcement as the completion of that effort, saying that after the merger closes, "all three phases of the Indivior Action Agenda will have been successfully completed."

The deal also follows a period in which Indivior's commercial decisions have rippled through treatment systems far beyond its home market. The company recently disclosed it will withdraw Sublocade from Australia by the end of 2026, a move Australian clinicians warned would destabilize patients stabilized on the monthly injection — a reminder of how much leverage a single manufacturer can hold over people recovering from opioid addiction.

What consolidation means for treatment access

The merger concentrates control of the leading long-acting opioid use disorder medication inside a larger, more diversified company with a stated appetite for further acquisitions. For treatment providers, the near-term picture is likely stability: Sublocade is the combined company's most valuable growth asset, and nothing in Monday's announcements suggested changes to supply or distribution.

The longer-term questions are about pricing power and competition. With exclusivity protected into the late 2030s and no direct long-acting rival at comparable scale, the combined Supernus will face little commercial pressure to lower Sublocade's cost — a persistent concern for state Medicaid programs, which are among the largest purchasers of addiction medications and which already operate under tightening federal eligibility rules. Whether a stronger balance sheet translates into broader patient assistance and access programs, or simply into shareholder returns, will be one of the first things treatment advocates watch for after the deal closes later this year.

If you or someone you know is struggling with opioid addiction, help is available. Visit SAMHSA's treatment locator or call 1-800-662-4357.